Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 6/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.45 |
| ▸ | CTSC | P53634 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSH | P09668 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16970557 | 0.98 | ACE (0.46) | MMEACECPA1ACE2LNPEP | |
| SCHEMBL16970519 | 0.92 | ACE (0.54) | MMEACECPA1ACE2LNPEP | |
| SCHEMBL16970534 | 0.91 | LTA4H (0.47) | MMECPA1LNPEPERAP2CTSB | |
| SCHEMBL16970535 | 0.90 | ACE (0.47) | MMEACECPA1ACE2LNPEP | |
| SCHEMBL16984914 | 0.88 | LNPEP (0.46) | MMELNPEPERAP2CTSCERAP1 | |
| SCHEMBL16970529 | 0.87 | CTSC (0.51) | MMEACECPA1ACE2CTSC | |
| SCHEMBL16984894 | 0.86 | LNPEP (0.44) | MMELNPEPERAP2CTSCCTSB | |
| SCHEMBL22472895 | 0.86 | LNPEP (0.53) | MMEACECPA1ACE2LNPEP | |
| SCHEMBL16970536 | 0.85 | CTSC (0.49) | MMEACECPA1ACE2CTSC | |
| SCHEMBL16984885 | 0.84 | MME (0.47) | MMELNPEPERAP2CTSBERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218212-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218212-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMA1, PSMB1, PSMB11 | MME 192/4885ACE 1134/4885CPA1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.